Skip to main content

China Patent Prosecution.

China Patent Prosecution:

China has its own patent prosecution system for granting patents to inventors and applicants. Patent prosecution in China involves the process of applying for a patent, examination by the Chinese Patent Office (China National Intellectual Property Administration - CNIPA), and, if the application meets the necessary requirements, the issuance of a patent.

The main steps in the patent prosecution process in China typically include:

1.Application Filing: 

The first step is to file a patent application with the CNIPA. The application can be for an invention, utility model, or design patent.

2.Examination: 

After filing, the CNIPA will examine the application to determine if it meets the necessary requirements and whether the invention is novel, non-obvious, and industrially applicable. This examination process can be quite thorough and may involve back-and-forth communication with the patent examiner.

3.Publication: 

Once the application is deemed to meet the requirements, it is published in the Chinese Patent Gazette.

4. Grant: 

If the application successfully passes examination, the CNIPA will grant the patent and issue the patent certificate.

It's important to note that China follows the "first-to-file" principle, meaning that the first person or entity to file a patent application for an invention will generally have priority over others who file for the same invention at a later date.

Navigating the patent prosecution process in China can be complex, especially for foreign applicants. Therefore, it's advisable to seek guidance from a qualified patent attorney with experience in Chinese patent law to ensure a smooth and successful application process. Additionally, be aware that patent laws and procedures may have changed since my last update in September 2021, so it's essential to refer to the latest official sources for up-to-date information.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcur...

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing ...

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys...